Magdalena Sierra Pacho-rekin lankidetzan egindako argitalpenak (8)

2024

  1. Blast Transformation of Chronic Myeloid Leukemia Driven by Acquisition of t(8;21)(q22;q22)/RUNX1::RUNX1T1: Selecting Optimal Treatment Based on Clinical and Molecular Findings

    Biomedicines, Vol. 12, Núm. 10

2015

  1. The cellular origin and malignant transformation of Waldenström macroglobulinemia

    Blood, Vol. 125, Núm. 15, pp. 2370-2380

2014

  1. Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: New criteria for differential diagnosis and risk stratification

    Leukemia, Vol. 28, Núm. 1, pp. 166-173

2011

  1. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

    Blood, Vol. 117, Núm. 13, pp. 3613-3616

2008

  1. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma

    British Journal of Haematology, Vol. 141, Núm. 2, pp. 212-215

2006

  1. The association of increased p14 ARF/p16 INK4a and p15 INK4b gene expression with proliferative activity and the clinical course of multiple myeloma

    Haematologica, Vol. 91, Núm. 11, pp. 1551-1554

2005

  1. Hematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11

    Cancer Genetics and Cytogenetics, Vol. 160, Núm. 1, pp. 68-72

2002

  1. The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma

    Hematology Journal, Vol. 3, Núm. 1, pp. 43-48